<table>
<thead>
<tr>
<th>YEAR</th>
<th>NO.</th>
<th>MANUSCRIPT</th>
<th>TRIAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>2</td>
<td>Ping Ng S, Leong T, Role of Radiation Therapy in Gastric Cancer, Ann Surg Oncol, March 2021.</td>
<td>TOPGEAR</td>
</tr>
<tr>
<td>2019</td>
<td>19</td>
<td>Segelow E, Sieber O, Chia JW, Williams DS, COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant asprin therapy. J Clin Oncol. 2018 Feb; 36 (4 suppl), 695</td>
<td>ASCOLT</td>
</tr>
</tbody>
</table>


IDEA (includes SCOT)

TACTIC

INTEGRATE

TROG 01.04

SCOT

MAX

TACTIC

ARCAD

TACTIC

TOPGEAR

INTEGRATE

TACTIC

TACTIC

TACTIC

TACTIC

TACTIC

TACTIC

February 2021

AGITG Publications-Manuscripts

Page 2 of 8


Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P, Clarke S, Iacopetta B. Molecular markers of response and
Hicks S, James R, Wong N, Tebbutt NC, Wilson S. A case study comparison of ethical review systems for multicentre
TRIAL
MANUSCRIPT
March 2021
tumors. An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. European
Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, Gebski V, Stockler MR. Assessment of health-related quality of
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro- Intestinal Trials Group (AGITG);
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid
Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid


<table>
<thead>
<tr>
<th>YEAR</th>
<th>NO.</th>
<th>MANUSCRIPT</th>
<th>TRIAL</th>
</tr>
</thead>
</table>